Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 5, 2012, Pages 563-574

  Bagi, Cedo Martin ^a   Gebhard, David F ^b   Andresen, Catharine J ^a  

^a GS and T   (United States)

^b PFIZER INC   (United States)

Author keywords

hepatocellular carcinoma; Huh7.5 HCC cells; orthotopic model; sunitinib; xenograft

Indexed keywords

PROTEIN P53; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER CIRCULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859419666     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328350916f     Document Type: Article

References (55)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
2. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19:3-23. (Pubitemid 40331495)
3. Thomas MB, Chadha R, Iwasaki M. The combination of bevacizumab and erlotinib shows significant biological activity in patients with advanced hepatocellular carcinoma. J Clin Oncol ASCO Annual Meeting Proceedings 2007; 25 (Suppl):214s.
4. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139:817-823.
5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750. (Pubitemid 29114292)
6. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/ doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97:1532-1538. (Pubitemid 41631953)
7. Lai EC, Choi TK, Cheng CH, Mok FP, Fan ST, Tan ES,Wong J. Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer 1990; 66:1685-1687. (Pubitemid 20381199)
8. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatology 1997; 27:854-861. (Pubitemid 27454829)
9. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007; 72 (Suppl 1):30-34.
10. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004; 39:1517-1524. (Pubitemid 38702652)
11. Zhang T, Sun HC, Xu Y, Zhang KZ, Wang L, Qin LX, et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 2005; 11:8557-8563. (Pubitemid 43005900)
12. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001; 46:149-168.
13. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Natl Med 2001; 7:987-989. (Pubitemid 32937367)
14. Peng R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cencer Lett 2006; 242:151-167. (Pubitemid 44485315)
15. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008; 14:1540-1549. (Pubitemid 351413939)
16. Bagi CM, Christensen J, Cohen DP, Roberts GW, Wilkie D, Swanson T, et al. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol Ther 2009; 8:1-10.
17. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Timedependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93:14765-14767.
18. Welker MW, Lubomierski N, Gog C, Herrmann E, Engels K, Vogl TJ, et al. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother 2010; 22:205-211.
19. DiMasi J, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22:151-185. (Pubitemid 36279392)
20. Bagi CM, Andresen CJ. Use of biomarkers in preclinical models of hepatocellular carcinoma. Cancers 2010; 2:1441-1452.
21. Allen M, Jones JL. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathology 2011; 223:162-176.
22. Hausser HJ, Brenner RE. Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun 2005; 333:216-222. (Pubitemid 40813467)
23. DeWever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathology 2003; 200:429-447. (Pubitemid 36818244)
24. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6:392-401.
25. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGFb signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303:848-851. (Pubitemid 38174665)
26. Amin J, Dore GJ, O'Connell DL, Barlett M, Tracey K, Kaldor JM, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol 2006; 45:197-203.
27. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801. (Pubitemid 23174709)
28. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337. (Pubitemid 36109749)
29. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial. Lancet 2006; 368:1329-1338. (Pubitemid 44528723)
30. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-3590.
31. Chang A, Kang Y, Lin J, Park J, Kudo M, Qin S, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol. ASCO Annual Meeting Proceedings, 2011; 29:4000.
32. Rubio-Viquieira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Therapeu 2009; 85:217-221.
33. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008; 112:250-259.
34. Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HY, Kim JS, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncology. ASCO Annual Meeting Proceedings Part I, 2007; 25:3546.
35. Ansorena E, Berasain C, Lopez Zabalza MJ, Avila MA, Garcia-Trevijano ER, Iraburu MJ. Differential regulation of the JNK/AP-1 pathway by Sadenosylmethionine and methylthioadenosine in primary rat hepatocytes versus HuH7 hepatoma cells. Am J Physiol Gastrointest Liver Physiol 2006; 290:G1186-G1193. (Pubitemid 43788301)
36. Huang S, He J, Zhang X, Bian Y, Yang L, Xie G, et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 2006; 27:1334-1340. (Pubitemid 43985408)
37. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, et al. Activation of Wnt/beta-catenin signaling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009; 100:1647-1658.
38. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69:223-240.
39. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15:225-236.
40. Palmer DH, Hussein SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Invest Drugs 2004; 13:1555-1568. (Pubitemid 39625141)
41. Yau T, Chan P, Epstein R, Ping Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009; 1:10-17.
42. Park SY, Seo EH, Song HS, Jung SY, Lee YK, Yi KY, et al. KR-31831 benzopyran derivative, inhibits VEGF-induced angiogenesis of HUVECs through suppressing KDR expression. Int J Oncol 2008; 32:1311-1315.
43. Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, Canuelo A, Nunez MI, Valenzuela MT, et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 2005; 386:119-125. (Pubitemid 40289231)
44. Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 2010; 8:35-45.
45. Fichtner I, SlisowW, Gill J, Becker M, Elbe B, Hillebrand T, Bibby M. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 2004; 40:298-307. (Pubitemid 38077034)
46. Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 2006; 12:4306-4314.
47. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12:4652-4661. (Pubitemid 44297818)
48. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:6146-6153.
49. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then recist RECIST. J Clin Oncol 2004; 22:4442-4445. (Pubitemid 41185107)
50. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96:189-195. (Pubitemid 46160619)
51. Sugino T, Yamaguchi T, Ogura G, Kusakabe T, Goodison S, Homma Y, Suzuki T. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via en invasionindependent pathway. J Pathol 2007; 212:152-160. (Pubitemid 46852093)
52. Ding T, Xu J, Zhang Y, Guo R-P, Wu W-C, Zhang S-D, et al. Endotheliumcoated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection. Cancer 2011; 117:4878-4889.
53. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systemic review. Eur J Cancer 2007; 43:979-992. (Pubitemid 46483030)
54. Mor E, Kaspa RT, Sheiner P, Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998; 129:643-653. (Pubitemid 28480821)
55. Ebos JML, Lee CR, Cruz-MunozW, Bjarnason GA, Christense JG, Kerbel RS. Accelerated metastases after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-239.